Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

NCT05272384 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05272384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05272384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
November 3, 2022
Completion date
June 28, 2027
Enrollment
32 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell non-hodgkin lymphoma, recurrent diffuse large b-cell lymphoma, recurrent hodgkin lymphoma, refractory b-cell non-hodgkin lymphoma, refractory diffuse large b-cell lymphoma, refractory hodgkin lymphoma